{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=cohort+4&page=28",
    "query": {
      "intervention": "cohort 4",
      "page": 28
    },
    "page_size": 10
  },
  "pagination": {
    "page": 28,
    "page_size": 10,
    "total_count": 3785,
    "total_pages": 379,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=cohort+4&page=29&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=cohort+4&page=27&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T02:29:06.220Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02389881",
      "title": "Safety, Tolerability, and Pharmacokinetics of Multiple-Dose TAK-058 in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "TAK-058",
          "type": "DRUG"
        },
        {
          "name": "TAK-058 Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 40,
      "start_date": "2015-02",
      "completion_date": "2015-12",
      "has_results": true,
      "last_update_posted_date": "2017-02-23",
      "last_synced_at": "2026-11-19T02:29:06.220Z",
      "location_count": 1,
      "location_summary": "Austsitn, Texas",
      "locations": [
        {
          "city": "Austsitn",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02389881"
    },
    {
      "nct_id": "NCT00941109",
      "title": "Escalation Study to Determine Bioavailability of a Single Oral Dose of Decitabine in Patients With Myelodysplastic Syndrome (MDS)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Myelodysplastic Syndrome"
      ],
      "interventions": [
        {
          "name": "decitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eisai Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2009-12",
      "completion_date": "2012-09",
      "has_results": false,
      "last_update_posted_date": "2023-06-18",
      "last_synced_at": "2026-11-19T02:29:06.220Z",
      "location_count": 6,
      "location_summary": "Scottsdale, Arizona • Denver, Colorado • Rochester, Minnesota + 3 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "The Bronx",
          "state": "New York"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00941109"
    },
    {
      "nct_id": "NCT00835328",
      "title": "Effect of Exendin (9-39) on Glucose Requirements to Maintain Euglycemia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Congenital Hyperinsulinism"
      ],
      "interventions": [
        {
          "name": "Exendin (9-39)",
          "type": "DRUG"
        },
        {
          "name": "Vehicle",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Diva De Leon",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "12 Months",
        "sex": "ALL",
        "summary": "Up to 12 Months"
      },
      "enrollment_count": 14,
      "start_date": "2009-08-26",
      "completion_date": "2017-01-28",
      "has_results": true,
      "last_update_posted_date": "2020-06-01",
      "last_synced_at": "2026-11-19T02:29:06.220Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00835328"
    },
    {
      "nct_id": "NCT02554812",
      "title": "A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Cancer"
      ],
      "interventions": [
        {
          "name": "Avelumab",
          "type": "DRUG"
        },
        {
          "name": "Utomilumab",
          "type": "DRUG"
        },
        {
          "name": "PF-04518600",
          "type": "DRUG"
        },
        {
          "name": "PD 0360324",
          "type": "DRUG"
        },
        {
          "name": "CMP-001",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 409,
      "start_date": "2015-11-09",
      "completion_date": "2023-03-23",
      "has_results": true,
      "last_update_posted_date": "2024-07-30",
      "last_synced_at": "2026-11-19T02:29:06.220Z",
      "location_count": 57,
      "location_summary": "Encinitas, California • La Jolla, California • Los Angeles, California + 23 more",
      "locations": [
        {
          "city": "Encinitas",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02554812"
    },
    {
      "nct_id": "NCT05988034",
      "title": "A Study to Assess the Effect of Avacopan at Therapeutic and Supratherapeutic Doses on the QT/QTc Interval in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Electrocardiography"
      ],
      "interventions": [
        {
          "name": "Avacopan",
          "type": "DRUG"
        },
        {
          "name": "Moxifloxacin",
          "type": "DRUG"
        },
        {
          "name": "Placebo for avacopan",
          "type": "DRUG"
        },
        {
          "name": "Placebo for moxifloxacin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 58,
      "start_date": "2019-11-08",
      "completion_date": "2020-03-31",
      "has_results": false,
      "last_update_posted_date": "2023-08-14",
      "last_synced_at": "2026-11-19T02:29:06.220Z",
      "location_count": 1,
      "location_summary": "Tempe, Arizona",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05988034"
    },
    {
      "nct_id": "NCT03502733",
      "title": "Testing the Combination of Copanlisib, Nivolumab and Ipilimumab in Patients With Advanced Cancer and Lymphoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lymphoma",
        "Metastatic Malignant Solid Neoplasm",
        "Recurrent Malignant Solid Neoplasm",
        "Unresectable Malignant Solid Neoplasm"
      ],
      "interventions": [
        {
          "name": "Biopsy Procedure",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Copanlisib",
          "type": "DRUG"
        },
        {
          "name": "Echocardiography Test",
          "type": "PROCEDURE"
        },
        {
          "name": "Ipilimumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 64,
      "start_date": "2018-08-14",
      "completion_date": "2027-08-01",
      "has_results": false,
      "last_update_posted_date": "2026-11-18",
      "last_synced_at": "2026-11-19T02:29:06.220Z",
      "location_count": 3,
      "location_summary": "Bethesda, Maryland • Houston, Texas",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03502733"
    },
    {
      "nct_id": "NCT06362252",
      "title": "A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Extensive Stage-small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Ifinatamab deruxtecan",
          "type": "DRUG"
        },
        {
          "name": "Atezolizumab",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Daiichi Sankyo",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 123,
      "start_date": "2024-07-22",
      "completion_date": "2028-02-20",
      "has_results": false,
      "last_update_posted_date": "2026-10-01",
      "last_synced_at": "2026-11-19T02:29:06.220Z",
      "location_count": 26,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 19 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06362252"
    },
    {
      "nct_id": "NCT03665285",
      "title": "A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced or Metastatic Solid Tumors",
        "Lung Cancer",
        "Breast Cancer",
        "Head and Neck Squamous Cell Carcinoma",
        "Endometrial Cancer",
        "Melanoma",
        "CRC",
        "Urothelial Carcinoma",
        "Cholangiocarcinoma"
      ],
      "interventions": [
        {
          "name": "NC318",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NextCure, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 109,
      "start_date": "2018-10-01",
      "completion_date": "2023-04-11",
      "has_results": true,
      "last_update_posted_date": "2024-03-08",
      "last_synced_at": "2026-11-19T02:29:06.220Z",
      "location_count": 6,
      "location_summary": "Los Angeles, California • New Haven, Connecticut • Hackensack, New Jersey + 3 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Hackensack",
          "state": "New Jersey"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Gettysburg",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03665285"
    },
    {
      "nct_id": "NCT04806035",
      "title": "Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "CLL",
        "SLL",
        "Richter's Transformation",
        "Indolent Lymphoma",
        "Follicular Lymphoma",
        "Marginal Zone Lymphoma",
        "Aggressive Lymphoma",
        "DLBCL",
        "Mediastinal Large B-cell Lymphoma",
        "MCL"
      ],
      "interventions": [
        {
          "name": "TG-1801",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ublituximab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "TG Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 21,
      "start_date": "2021-04-28",
      "completion_date": "2024-06-12",
      "has_results": false,
      "last_update_posted_date": "2024-07-31",
      "last_synced_at": "2026-11-19T02:29:06.220Z",
      "location_count": 5,
      "location_summary": "Fayetteville, Arkansas • Hackensack, New Jersey • Chattanooga, Tennessee + 2 more",
      "locations": [
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Hackensack",
          "state": "New Jersey"
        },
        {
          "city": "Chattanooga",
          "state": "Tennessee"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04806035"
    },
    {
      "nct_id": "NCT07630168",
      "title": "Effects of Infusion Timing on Treatment Response in Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lung Cancer",
        "Non-small Cell Lung Cancer",
        "Metastatic Lung Cancer",
        "Head and Neck Cancer",
        "Metastatic Squamous Cell Carcinoma",
        "Metastatic Head and Neck Cancer",
        "Resectable Head and Neck Squamous-cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "PD-1/PD-L1 inhibitor monotherapy - 4 cycles before 12:00PM",
          "type": "DRUG"
        },
        {
          "name": "PD-1/PD-L1 inhibitor monotherapy - 4 cycles after 3 PM",
          "type": "DRUG"
        },
        {
          "name": "PD-1 inhibitor monotherapy - 2 cycles before 12:00PM",
          "type": "DRUG"
        },
        {
          "name": "PD-1 inhibitor monotherapy - 2 cycles after 3 PM",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "UNC Lineberger Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 238,
      "start_date": "2026-08-03",
      "completion_date": "2033-01-01",
      "has_results": false,
      "last_update_posted_date": "2026-09-15",
      "last_synced_at": "2026-11-19T02:29:06.220Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07630168"
    }
  ]
}